VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
A phase 1/2 trial of Pembrolizumab in salivary gland cancers and non-small-cell lung cancer, run by VM Oncology, LLC, now recruiting.
Overview
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma is a phase 1/2 interventional study registered as NCT03556228 by VM Oncology, LLC, with 242 participants planned, started 2018-06-08 and due to reach its primary completion in 2027-12. Interventions recorded: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg). Conditions listed: Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- PersonMichael Boyer
Shares Mesothelioma, Head and neck squamous cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialClinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
Shares Salivary gland cancers, Head and neck squamous cell carcinoma.
- PersonKaren Kelly
Shares Mesothelioma, Small-cell lung cancer, Non-small-cell lung cancer.
- JournalThoracic cancer
Shares Mesothelioma, Small-cell lung cancer, Non-small-cell lung cancer.
- JournalHead and neck pathology
Shares Salivary gland cancers, Head and neck squamous cell carcinoma.
- TrialTT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Shares Mesothelioma, Non-small-cell lung cancer.
- PersonAlfredo Addeo
Shares Mesothelioma, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Shares Mesothelioma, Small-cell lung cancer, Non-small-cell lung cancer.